Aligos Therapeutics (NASDAQ:ALGS) Trading 6.3% Higher – Still a Buy?

Posted by George Bondi on Jul 2nd, 2026

Aligos Therapeutics, Inc. (NASDAQ:ALGS – Get Free Report) shares shot up 6.3% on Tuesday . The company traded as high as $5.85 and last traded at $5.77. 104,179 shares were traded during trading, an increase of 38% from the average daily volume of 75,308 shares. The stock had previously closed at $5.43.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Aligos Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Sunday, May 17th. Weiss Ratings downgraded shares of Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 25th. HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Aligos Therapeutics in a research report on Wednesday, March 11th. Cantor Fitzgerald restated an “overweight” rating on shares of Aligos Therapeutics in a research note on Friday, May 29th. Finally, Westpark Capital initiated coverage on Aligos Therapeutics in a research note on Thursday, March 26th. They issued a “buy” rating and a $48.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $38.50.

Get Our Latest Stock Report on Aligos Therapeutics

Aligos Therapeutics Price Performance

The firm has a market capitalization of $34.60 million, a price-to-earnings ratio of -0.64 and a beta of 2.26. The firm’s 50-day simple moving average is $5.72 and its 200 day simple moving average is $7.26.

Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported ($2.21) earnings per share for the quarter, beating the consensus estimate of ($2.29) by $0.08. The business had revenue of $2.83 million for the quarter, compared to analyst estimates of $0.25 million. Aligos Therapeutics had a negative return on equity of 139.47% and a negative net margin of 1,919.68%. As a group, research analysts predict that Aligos Therapeutics, Inc. will post -7.47 earnings per share for the current year.

Institutional Investors Weigh In On Aligos Therapeutics

Several hedge funds have recently added to or reduced their stakes in ALGS. Woodline Partners LP bought a new stake in shares of Aligos Therapeutics in the 1st quarter valued at about $2,602,000. Marshall Wace LLP acquired a new stake in shares of Aligos Therapeutics in the 4th quarter valued at about $2,504,000. Bank of America Corp DE lifted its holdings in shares of Aligos Therapeutics by 1,652.8% in the 1st quarter. Bank of America Corp DE now owns 229,754 shares of the company’s stock worth $1,707,000 after purchasing an additional 216,646 shares in the last quarter. SummitTX Capital L.P. acquired a new position in shares of Aligos Therapeutics during the fourth quarter valued at about $1,299,000. Finally, Verition Fund Management LLC bought a new stake in Aligos Therapeutics during the 4th quarter worth approximately $664,000. 60.43% of the stock is currently owned by institutional investors and hedge funds.

Aligos Therapeutics Company Profile

(Get Free Report)

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.